TMCnet News
Inclusion Body Myositis (IBM) - Pipeline Review, H2 2017 - Research and MarketsThe "Inclusion Body Myositis (IBM) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Inclusion Body Myositis (IBM (News - Alert)) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed b Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/qls5f6/inclusion_body?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171218006009/en/ |
